Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is neurofibroma (including plexiform)?
A neurofibroma is a tumor that grows from the cells that wrap and support nerves (the nerve sheath). The great majority of neurofibromas are benign, meaning they are not cancer and do not spread to other parts of the body. They can appear as soft bumps on or just under the skin, or grow more deeply along a nerve. Many people have a single neurofibroma with no underlying condition, but neurofibromas are also the hallmark tumor of neurofibromatosis type 1 (NF1), a genetic condition in which people develop many of them over a lifetime. A particular form called a plexiform neurofibroma grows in a tangled, rope-like way through and around a network of nerves; these are present from early in life in NF1, can become large, and may cause pain, disfigurement, or pressure on nearby structures. The reason neurofibromas matter medically is twofold. First, even though they are benign, large or plexiform tumors can press on nerves, the spine, the airway, or other organs and cause real symptoms. Second, in people with NF1 a plexiform neurofibroma carries a small but important lifetime risk of transforming into a cancer called a malignant peripheral nerve sheath tumor (MPNST) — so new pain, rapid growth, or a firming-up of a previously soft tumor is a warning sign that should be evaluated promptly. Most ordinary neurofibromas simply need observation. When treatment is needed, surgery has long been the main option, and a newer class of targeted medicines (MEK inhibitors) can shrink plexiform tumors that cannot be safely removed. Radiation has only a limited, carefully chosen role here, because in a genetic nerve-tumor syndrome it can raise the long-term risk of new tumors.
The main types
Doctors group neurofibroma (including plexiform) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Cutaneous (skin) neurofibroma | Soft bumps on or just beneath the skin; benign, often multiple in NF1, and treated only for symptoms or cosmetic reasons. |
| Solitary (sporadic) neurofibroma | A single neurofibroma in someone without NF1; benign and usually cured by simple removal if it causes symptoms. |
| Plexiform neurofibroma | A tumor that grows in a tangled way through a network of nerves, usually in NF1; can become large, cause symptoms, and carries a small risk of turning into a cancer over time. |
| Spinal/paraspinal neurofibroma | A neurofibroma growing from nerve roots near the spine that can press on the spinal cord or nerves and may need surgery or focused radiation. |
| Malignant peripheral nerve sheath tumor (MPNST) | The cancer that can rarely arise from a plexiform neurofibroma; this is treated aggressively with surgery, and radiation and chemotherapy, very differently from a benign neurofibroma. |
Staging, in plain terms
Because the typical neurofibroma is benign, it is not given a cancer stage the way most tumors are. Instead, doctors describe it by what matters for treatment: whether it is a single tumor or part of NF1, whether it sits in the skin or deep along a nerve or near the spine, how large it is, and whether it is causing symptoms such as pain, weakness, or pressure on nearby organs. The single most important judgment for a plexiform neurofibroma in NF1 is whether it is changing. A benign plexiform tumor is usually soft and slow-growing, but new or worsening pain, rapid growth, a previously soft area becoming hard, or new nerve problems can signal that part of it has transformed into a malignant peripheral nerve sheath tumor (MPNST). When that is suspected, imaging — often including a PET scan — and a biopsy are used to look for cancer. Only at that point does formal staging come into play, and it follows the system used for soft-tissue sarcomas (size, depth, grade, and whether it has spread). So for the benign neurofibroma itself, the framework is observation and symptom-based decisions; the staging conversation belongs to the uncommon situation where a tumor has become cancerous.
| No formal cancer stage for benign neurofibroma — managed by symptoms, size, location, and watching for change; MPNST is staged as a soft-tissue sarcoma | What it generally means |
|---|---|
| Asymptomatic / incidental | A neurofibroma causing no problems; usually just watched, with no treatment needed. |
| Symptomatic but benign | A tumor causing pain, disfigurement, or pressure on nerves or organs; managed with surgery, a targeted medicine for plexiform tumors, or selectively radiation. |
| Concerning for transformation | New pain, rapid growth, or firming of a plexiform tumor in NF1; evaluated promptly with imaging and biopsy to rule out cancer. |
| MPNST (cancerous) | A nerve-sheath cancer that has arisen from a neurofibroma; staged and treated as a soft-tissue sarcoma with surgery, radiation, and sometimes chemotherapy. |
The standard of care
Neurofibroma (including Plexiform) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Observation (active surveillance)
Most benign neurofibromas are simply monitored with periodic exams and, for plexiform tumors, occasional imaging — treatment is reserved for those that cause symptoms or change.
Surgery
Removal is the main treatment for a symptomatic neurofibroma; for plexiform tumors entwined with nerves, surgeons remove what they safely can, sometimes in stages, to relieve symptoms while protecting nerve function.
Targeted therapy (MEK inhibitor)
An oral medicine such as selumetinib can shrink plexiform neurofibromas in NF1 that cannot be safely removed, easing pain and pressure — a major advance for tumors once considered untreatable.
Radiation therapy (selective)
Used cautiously and only in specific situations — for example, a tumor near the spine that can't be removed — because radiation can raise the long-term risk of new tumors or transformation in NF1.
Multidisciplinary NF care
People with NF1 are followed by a team that watches for new tumors and other features of the condition and coordinates genetic counseling for the family.
How radiation treatment works
Radiation therapy works by delivering focused energy that damages the DNA inside tumor cells so they can no longer grow and divide. For neurofibromas, the role of radiation is deliberately limited, and understanding why explains how it is used. Most neurofibromas are benign and either need no treatment or are best handled by surgery or, for plexiform tumors, a targeted oral medicine. On top of that, the majority of plexiform neurofibromas occur in people with neurofibromatosis type 1 (NF1), a genetic condition in which cells are already more prone to forming tumors; radiation to such tissue can raise the long-term risk of new tumors or of a benign tumor transforming into a cancer. For these reasons, radiation is not a routine treatment for benign neurofibromas and is reserved for carefully selected situations — for instance, a tumor near the spine or skull base that is causing problems and cannot be safely removed, where highly focused techniques such as stereotactic radiosurgery can control it while sparing nearby nerves and the spinal cord. Radiation takes on a much larger and more standard role if a neurofibroma transforms into a malignant peripheral nerve sheath tumor (MPNST). In that cancerous setting, radiation is used much as it is for other soft-tissue sarcomas: given before or after surgery to treat the microscopic disease that extends beyond the visible tumor and to reduce the chance the cancer comes back locally. Modern delivery — intensity-modulated radiation or proton therapy — concentrates the dose on the target and limits exposure to surrounding nerves and growing tissue, which matters most in younger patients and those with NF1. In short, for benign neurofibromas radiation is a niche tool used with caution, while for the cancer that can rarely arise from them it becomes a central part of curative treatment.
The main ways radiation is delivered for neurofibroma (including plexiform):
Stereotactic radiosurgery / focused radiation
Highly focused beams can control a benign nerve-sheath tumor that sits in a hard-to-reach spot, such as near the spine or skull base, when surgery would be too risky — used selectively because of the syndrome-related risk profile.
Adjuvant radiation for MPNST
When a neurofibroma has transformed into a cancer (MPNST), radiation before or after surgery treats microscopic disease around the tumor bed and lowers the chance of local recurrence, as it does for other soft-tissue sarcomas.
Intensity-modulated / proton radiation
Shaping the dose tightly around the target — or using proton beams — spares surrounding nerves, spinal cord, and developing tissue, which is especially important in younger patients and in NF1.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Targeted therapy shrinks inoperable plexiform tumors: Trials of the MEK inhibitor selumetinib in children with NF1 showed meaningful shrinkage of plexiform neurofibromas and reduced pain, leading to approval and changing the outlook for tumors that could not be removed surgically.[1]
Selumetinib NF1 plexiform neurofibroma trials
Radiation in NF1 carries added long-term risk: Studies in neurofibromatosis type 1 have linked radiation exposure to a higher risk of second tumors and malignant transformation, supporting the cautious, selective use of radiation for benign nerve-sheath tumors in this population.[2]
NF1 radiation second-tumor risk literature
Combined surgery and radiation for MPNST: When a neurofibroma transforms into a malignant peripheral nerve sheath tumor, complete surgical removal with radiation gives the best chance of local control, underscoring the importance of catching transformation early.[3]
MPNST multimodality treatment series
Common questions
Is a neurofibroma cancer? Almost always, no. The typical neurofibroma is benign — not cancer — and does not spread. Many cause no problems and simply need watching. The important exception is in people with NF1, where a plexiform neurofibroma carries a small lifetime risk of transforming into a cancer called MPNST, which is why new pain, rapid growth, or a tumor becoming hard should be checked promptly.
How are neurofibromas treated if they cause problems? Surgery is the main option for a symptomatic neurofibroma. For plexiform tumors in NF1 that cannot be safely removed, a targeted oral medicine (a MEK inhibitor) can shrink the tumor and ease symptoms. Radiation is used only in select situations, such as a tumor near the spine that can't be operated on, because in NF1 it can raise long-term tumor risk.
Why is radiation used so cautiously for neurofibromas? Most neurofibromas are benign and have good non-radiation options, and many occur in people with NF1, whose tissue is already prone to forming tumors. Radiation can increase the long-term risk of new tumors or of transformation in that setting, so it is reserved for carefully chosen cases. If a neurofibroma becomes a cancer (MPNST), radiation then plays a standard and important role alongside surgery.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.